Search Results for "Ranbaxy Launches Atorvastatin In Us"

05:21 EST 27th January 2015 | BioPortfolio

Matching Channels


Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is pres...

Matching News

U.S. Pay-To-Delay Suit Against Ranbaxy, Pfizer Rejected

A U.S. judge threw out a suit filed against Ranbaxy Laboratories and Pfizer alleging they colluded to delay the market introduction of a generic of the top-selling Lipitor (atorvastatin) for high chol...

Ranbaxy launches J&J biosimilar in India

Ranbaxy has launched the first biosimilar of Johnson & Johnson’s Remicade (infliximab) in India, marking the firm’s entry into monoclonal antibodies biologics. The biosimilar, which will be ma...

EPIRUS Biopharmaceuticals Remicade Biosimilar Launches in India

Infimab (BOW015) launches one quarter ahead of schedule with commercialisation partner Ranbaxy Laboratories

UPDATE 1-Ranbaxy says Europe bars imports from antibiotic injectables unit

* Ranbaxy says sees no significant impact on business (Recasts with statements from Ranbaxy and European regulator, adds details)

Cipher Pharmaceuticals signs distribution agreement with Ranbaxy

MISSISSAUGA, ON- Cipher Pharmaceuticals Inc. announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Ltd., granting Ranbaxy exclusive rights to market, sell and dis...

U.S. FDA Slams Ranbaxy’s Claims In Nexium, Valcyte Lawsuit

The federal drug regulatory agency highlighted Ranbaxy’s faulty manufacturing practices, strongly retaliating to Ranbaxy’s claims in a lawsuit challenging its decision to rescind tentative approva...

FDA revokes tentative approval of Ranbaxy’s generic Nexium and Valcyte

Indian generics drugmaker Ranbaxy Laboratories revealed in a Bombay Stock Exchange filing that it has received communication from the US Food and Drug Administration, in which the agency said it has d...

EPIRUS Biopharmaceuticals Remicade Biosimilar, Infimab, Launches in India

Infimab (BOW015) Launches one quarter ahead of schedule with commercialization partner Ranbaxy Laboratories Limited EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharma...

Matching PubMed Articles

Can atorvastatin calcium cause asymptomatic hypercalcemia?

The use of statins may have unnatural effects. A 54-year-old woman was admitted to the hospital with an incidental finding of hypercalcemia (10.8 mg/dL). There was no disease other than hyperlipidemia...

Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial.

Background. Treatment of hyperlipidemia is helpful in both primary and secondary prevention of coronary heart disease and stroke. Aim. To compare lipid-lowering efficacy of rosuvastatin with atorvasta...

The Effect of Atorvastatin and Atorvastatin-Ezetimibe Combination Therapy on Androgen Production in Hyperandrogenic Women with Elevated Cholesterol Levels.

Statins decreased serum androgen levels in hyperandrogenemic women with polycystic ovary syndrome. No previous study has investigated whether this effect is dose-dependent and observed in patients sim...

Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.

Objective: Endothelial function is an independent predictor of prognosis in heart failure (HF) subjects. Statins, beyond their lipid lowering role, exert beneficial effect in patients with atheroscler...

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Guidelines endorse statin therapy for lowering low-density lipoprotein cholesterol (LDL-C) to recommended levels, in patients with cardiovascular disease (CVD) risk, if needed, after lifestyle changes...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement